Abivax (NASDAQ:ABVX) Shares Gap Up – Should You Buy?

Abivax SA Sponsored ADR (NASDAQ:ABVX) shares gapped up prior to trading on Monday . The stock had previously closed at $142.31, but opened at $147.00. Abivax shares last traded at $142.64, with a volume of 285,247 shares traded.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ABVX. Wolfe Research raised shares of Abivax to a “strong-buy” rating in a research note on Thursday, November 6th. Citigroup reiterated an “outperform” rating on shares of Abivax in a report on Tuesday, December 16th. Piper Sandler restated an “overweight” rating and issued a $142.00 target price on shares of Abivax in a research note on Tuesday, December 16th. Truist Financial set a $140.00 target price on Abivax in a research report on Monday, November 24th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $175.00 price target on shares of Abivax in a research report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $128.73.

Abivax Stock Up 0.4%

The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. The company has a market cap of $11.14 billion, a P/E ratio of -34.21 and a beta of 0.49. The firm’s 50-day simple moving average is $113.55 and its 200 day simple moving average is $77.08.

Abivax (NASDAQ:ABVX) last announced its earnings results on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The company had revenue of ($4.92) million for the quarter. On average, research analysts forecast that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Abivax

Several institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC lifted its holdings in shares of Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after acquiring an additional 369 shares during the last quarter. First Horizon Corp acquired a new position in Abivax during the 3rd quarter worth about $36,000. Bank of America Corp DE boosted its holdings in Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after acquiring an additional 1,990 shares during the last quarter. Hantz Financial Services Inc. acquired a new stake in shares of Abivax during the third quarter worth $52,000. Finally, Cubist Systematic Strategies LLC raised its position in shares of Abivax by 34.3% in the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after acquiring an additional 2,595 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.